Translating New Updates on Efficacy of TKIs into Chronic Myelogenous Leukemia (CML) Therapy Practice | Satellite Symposium

Satellite Symposium Agenda:

Expert Talk 1: Chronic Myelogenous Leukemia (CML)- Monitoring & Mechanisms of resistance

Ehab Atallah

*Section Head, hematological malignancies, Medical College of Wisconsin, Milwaukee, WI, USA Expert Talk 2: Outcomes with Second Line or Later Treatment in CML

Kendra Sweet

*Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA. Expert Talk 3: Do we need new TKIs for CML therapy? Yes ! Why ?

Giuseppe Saglio

*Division of Internal Medicine and Haematology, University of Turin, Turin, Italy. Expert Panel Discussion and Questions & Answers

Panelists: Ehab Atallah, Giuseppe Saglio and Kendra Sweet

Section Head, hematological malignancies, Medical College of Wisconsin, Milwaukee, WI, USA, Division of Internal Medicine and Haematology, University of Turin, Turin, Italy & *Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA

Learning Objectives:

After completing the independent medical educational activity, learners will be able to:

1. Improve learners knowledge and understanding about latest evidence-based findings about TKIs efficacy in CML patients with failed prior lines of therapies.

2. Based on the knowledge learned from the activity, learners will be able to develop effective strategies regarding TKIs usage in CML patients with failed prior lines of therapies.

Certificate of attendance: The certificates will be given to those attendees who will complete pre & post symposium evaluation quiz.

Conflict of interests: No known conflict of interests

Acknowledgment: This symposium is supported by an educational grant from Pfizer.